Ongoing Clinical Trials for Retinopathy Proliferative
Currently, there is 1 ongoing clinical trial investigating new treatment approaches for retinopathy proliferative, a serious eye condition affecting premature infants. This trial is testing dexamethasone eye drops as a potential way to prevent the progression of the disease and reduce the need for conventional treatments. The study is being conducted in Sweden and focuses on infants born before 30 weeks of pregnancy. (Also known as: Retinopathy of Prematurity, ROP)
Clinical trial locations
Study on Dexamethasone Eye Drops for Infants with Retinopathy of Prematurity
This trial is exploring whether dexamethasone eye drops can help prevent the progression of retinopathy of prematurity in very premature infants. The condition occurs when abnormal blood vessels grow in the retina, the light-sensitive tissue at the back of the eye, which can potentially lead to vision problems or even retinal detachment if left untreated.
Who can participate:
- Babies born before 30 weeks of pregnancy
- Infants diagnosed with specific types and stages of retinopathy of prematurity, confirmed through special eye photography called RetCam and verified by two eye doctors
- This includes babies with Zone I disease at Stage 1 or 2 without plus disease, or Zone II disease at Stage 2 or 3 in certain locations
- Parents must provide informed consent after receiving detailed information about the study
Who cannot participate:
- Infants with other serious eye conditions besides retinopathy of prematurity
- Babies who have already had eye surgery
- Infants currently receiving other treatments that might interfere with the study
- Babies with known allergies to dexamethasone or any of its components
- Infants with other serious health conditions that doctors believe would make participation unsafe
What the trial involves:
The study is testing dexamethasone eye drops, which is a steroid medication that helps reduce inflammation. The main goal is to see whether these eye drops can reduce the number of infants who need standard treatments for the condition. Participants will receive either the dexamethasone eye drops or a placebo, and researchers will monitor whether the medication helps prevent the disease from getting worse.
Throughout the study, doctors will closely monitor the infants’ eyes through regular examinations. They will measure eye pressure before treatment starts, at 1 and 2 weeks after beginning treatment, and after treatment is completed. Follow-up evaluations will continue at 40 weeks postmenstrual age and at 2 and 5.5 years of age to assess long-term eye health and vision outcomes. Additional tests may include optical coherence tomography, a special imaging technique that examines the structure of the retina in detail.
The study will also analyze leftover blood samples from routine clinical tests to look for biological markers that might be related to how the disease develops and how well the treatment works.
Investigational drug: Dexamethasone eye drops are being tested for their ability to suppress inflammation and reduce abnormal blood vessel growth in the eye. As a corticosteroid, dexamethasone mimics hormones naturally produced by the body to control inflammation. The medication is applied directly to the eyes in drop form.
Summary
Currently, research into new treatments for retinopathy proliferative is focused on Sweden, where one trial is investigating an anti-inflammatory approach using dexamethasone eye drops. This study represents an important effort to find less invasive treatment options for very premature infants at risk of vision problems. The trial focuses specifically on early-stage disease, aiming to prevent progression before more aggressive treatments become necessary. The long-term follow-up period, extending to 5.5 years of age, demonstrates a commitment to understanding not just immediate effects but also the lasting impact on children’s vision as they grow. The study is expected to conclude by the end of 2024.